Release Date: Thursday, July 24, 2014
Expiration Date: Thursday, July 23, 2015
Estimated Time To Complete Activity: 1 hour
To participate in this activity, please click the 'Launch Video' button above.
For optimal viewing of this activity please use
Internet Explorer or Google Chrome as your
browser. Firefox is currently not supported.
This Web archive is based on the proceedings from the live meeting series entitled,"The Evolving Treatment Landscape for Metastatic Pancreatic Cancer: Clinical Advances for You and Your Patients."
For optimal viewing of this activity please use Internet Explorer or Google Chrome as your browser. Firefox is currently not supported.
Individuals who have successfully received credit for participation in a live meeting of this activity are not eligible to receive credit for this enduring material.
Andrew H. Ko, MD
University of California, San Francisco
This activity is designed for medical oncologists, gastroenterologists, radiation oncologists, surgical oncologists, pathologists, and other healthcare professionals involved in the treatment of patients with pancreatic cancer.
At the conclusion of this activity, participants should be able to:
- Implement appropriate treatment plans for patients with metastatic pancreatic cancer based on recent clinical data and current clinical guidelines
- Compare the roles and mechanisms of action of current therapeutic approaches for the treatment of metastatic pancreatic cancer
- Evaluate recent trial data for novel agents in pancreatic cancer, including how these options may be integrated into the treatment paradigm
- Accreditation Statement
- This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Andrew H. Ko, MD
University of California, San Francisco Consulting Fee, OncoGenex Pharmaceuticals, Inc., Celgene Corporation, Threshold Pharmaceuticals; Contracted Research, Infinity Pharmaceuticals, Inc., PharmaEngine Inc., Seattle Genetics, Inc., Lilly/ImClone.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS, Jocelyn Timko, BS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Jointly provided by:
This activity is supported by an educational grant provided by Celgene Corporation.